Biotechnology firm Galapagos has started dosing patients in its Phase II EQUATOR clinical trial of filgotinib for the treatment of moderately to severely active psoriatic arthritis.

Developed using the firm's target and drug discovery technology platform, filgotinib is an investigational, highly selective JAK1 inhibitor.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Galapagos has entered global collaboration with Gilead to develop and commercialise filgotinib in inflammatory indications.

The first dosing in this Phase II trial is set to trigger a $10m milestone payment from Gilead.

The multi-centre, randomised, double-blind, placebo-controlled EQUATOR trial is designed to evaluate the safety and efficacy of filgotinib in 124 adults who are intolerant or have an inadequate response to standard disease-modifying therapy.

"The trial's primary objective is the measure of percentage of patients who have reached ACR20 response when compared to placebo."

The trial's primary objective is the measure of percentage of patients who have reached ACR20 response when compared to placebo.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The secondary outcome measures include minimal disease activity (MDA), percentage of participants reaching ACR50 and ACR70 responses, and measure of psoriatic arthritis response criteria compared to placebo.

The trial will also assess percentage of subjects gaining DAS28 (CRP) score, SDAI response, CDAI response and EULAR response in addition to psoriatic arthritis response criteria (PsARC).

Filgotinib is also being studied in TORTUGA Phase II clinical trial for ankylosing spondylitis, FINCH Phase III programme to treat rheumatoid arthritis, DIVERSITY Phase III trial for Crohn's disease, SELECTION Phase IIb/III trial in ulcerative colitis and Phase II trial for Sjögren's syndrome.   

Galapagos discovers and develops small-molecule drugs for multiple indications such as cystic fibrosis, inflammation, fibrosis and osteoarthritis.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact